| Is liraglutide a useful addition to diabetes therapy? | |
| | |
MedLine Citation:
|
PMID: 20439238 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate liraglutide as an antidiabetic agent. METHODS: The pertinent English-language medical literature was reviewed for the period from 1985 to April 2010 with use of data from MEDLINE. RESULTS: Liraglutide is a glucagonlike peptide-1 receptor analogue that stimulates insulin secretion, reduces postprandial glucagon release, causes a mild delay in gastric emptying, and may slightly decrease appetite. Mean reductions in hemoglobin A1c levels with liraglutide therapy range from 1.0% to 1.5% in comparison with baseline and are 1.0% and 1.3% in comparison with placebo. Head-to-head trials suggest that liraglutide may be more effective than glimepiride, rosiglitazone, insulin glargine, and exenatide. Some of the previous trials, however, are limited by use of submaximal doses of comparator drugs and an open-label design. The use of liraglutide is associated with a mean weight loss of 0.2 to 3.2 kg relative to baseline and 0.1 to 2.6 kg relative to placebo. Liraglutiderelated hypoglycemia is generally mild, but its incidence and severity substantially increase in conjunction with sulfonylureas. Gastrointestinal adverse effects such as nausea, diarrhea, or vomiting occurred in 44% to 56% of patients who received liraglutide versus 17% to 19% with placebo. Premature withdrawal from trials occurred in 4% to 15% of liraglutide-treated patients (mainly attributable to gastrointestinal adverse effects), in comparison with 3% to 5% of those receiving placebo. CONCLUSION: The 2 main advantages of liraglutide are mild degrees of weight loss and hypoglycemia. Important limitations, however, are the frequent occurrence of gastrointestinal adverse effects, the requirement of subcutaneous injection once daily, and the lack of long-term efficacy and safety data. Liraglutide may be a useful add-on therapy in patients with type 2 diabetes uncontrolled with metformin, when hypoglycemia, weight gain, or both are major concerns. |
| | |
Authors:
|
Nasser E Mikhail |
Related Documents
:
|
17065668 - Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. 9740498 - Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. 12652358 - Rationale and options for combination therapy in the treatment of type 2 diabetes. 16370928 - Is exenatide advancing the treatment of type 2 diabetes? 1709028 - Interaction among zinc, glucose, and insulin in normal individuals during glucose and t... 9195388 - Review: nonalcoholic steatohepatitis. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: 16 ISSN: 1934-2403 ISO Abbreviation: Endocr Pract Publication Date: 2010 Nov-Dec |
Date Detail:
|
Created Date: 2011-01-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: United States |
Other Details:
|
Languages: eng Pagination: 1028-37 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of California Medical Center, Sylmar, CA, USA. nmikhail@dhs.lacounty.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Salt sensitivity, insulin resistance, and public health in India.
Next Document: Unusual manifestation of parathyroid carcinoma in the setting of papillary thyroid cancer.